Get started
Author

Laurence Chu

Observed names: Chu, Laurence, L Chu, L. Chu
ORCID: 0000-0002-8950-6117
Observed ORCID: 0000-0002-8950-6117
OpenAlex ID: A5061349411
Safety and immunogenicity of SARS-CoV-2 variant mRNA vaccine boosters in healthy adults: an interim analysis
2021 · Angela Choi, Matthew Koch, et al. · Nature Medicine · 375
PDF
A preliminary report of a randomized controlled phase 2 trial of the safety and immunogenicity of mRNA-1273 SARS-CoV-2 vaccine
2021 · Laurence Chu, Roderick McPhee, et al. · Vaccine · 223
PDF
The safety and immunogenicity of two Zika virus mRNA vaccine candidates in healthy flavivirus baseline seropositive and seronegative adults: the results of two randomised, placebo-controlled, dose-ranging, phase 1 clinical trials
2023 · Brandon Essink, Laurence Chu, et al. · The Lancet Infectious Diseases · 154
Safety and immunogenicity of the rVSV∆G-ZEBOV-GP Ebola virus vaccine candidate in healthy adults: a phase 1b randomised, multicentre, double-blind, placebo-controlled, dose-response study
2017 · D Gray Heppner, Tracy L Kemp, et al. · The Lancet Infectious Diseases · 122
Immune response to SARS-CoV-2 after a booster of mRNA-1273: an open-label phase 2 trial
2022 · Laurence Chu, Keith Vrbicky, et al. · Nature Medicine · 101
PDF
Safety and Immunogenicity of an mRNA-Based Human Metapneumovirus and Parainfluenza Virus Type 3 Combined Vaccine in Healthy Adults
2022 · Allison August, Christine A Shaw, et al. · Open Forum Infectious Diseases · 93
PDF
Safety and immunogenicity of a vaccine for extra-intestinal pathogenic Escherichia coli (ESTELLA): a phase 2 randomised controlled trial
2019 · Robert W Frenck, John Ervin, et al. · The Lancet Infectious Diseases · 91
Six-Month Safety Data of Recombinant Vesicular Stomatitis Virus–Zaire Ebola Virus Envelope Glycoprotein Vaccine in a Phase 3 Double-Blind, Placebo-Controlled Randomized Study in Healthy Adults
2017 · Scott A. Halperin, Jose R. Arribas, et al. · The Journal of Infectious Diseases · 81
PDF
Safety, Immunogenicity, and Efficacy of the NVX-CoV2373 COVID-19 Vaccine in Adolescents
2023 · Germán Áñez, Lisa M. Dunkle, et al. · JAMA Network Open · 59
PDF
Safety and Immunogenicity of 3 Formulations of an Investigational Respiratory Syncytial Virus Vaccine in Nonpregnant Women: Results From 2 Phase 2 Trials
2018 · Jiři Beran, Jason D Lickliter, et al. · The Journal of Infectious Diseases · 46
PDF
Reactogenicity, safety, and immunogenicity of chimeric haemagglutinin influenza split-virion vaccines, adjuvanted with AS01 or AS03 or non-adjuvanted: a phase 1–2 randomised controlled trial
2022 · Nicolas Folschweiller, Carline Vanden Abeele, et al. · The Lancet Infectious Diseases · 35
Time to Change Dosing of Inactivated Quadrivalent Influenza Vaccine in Young Children: Evidence From a Phase III, Randomized, Controlled Trial
2016 · Varsha K. Jain, Joseph B. Domachowske, et al. · Journal of the Pediatric Infectious Diseases Society · 35
Persistence of Antibodies to 2 Virus-Like Particle Norovirus Vaccine Candidate Formulations in Healthy Adults: 1-Year Follow-up With Memory Probe Vaccination
2019 · Robert L Atmar, Frank Baehner, et al. · The Journal of Infectious Diseases · 30
Clinical and Demographic Factors Associated With COVID-19, Severe COVID-19, and SARS-CoV-2 Infection in Adults
2023 · Deborah A. Theodore, Angela R. Branche, et al. · JAMA Network Open · 24
PDF
Risk of COVID-19 after natural infection or vaccination
2023 · Anne-Marie Rick, Matthew B. Laurens, et al. · EBioMedicine · 21
PDF
A Bivalent Omicron-BA.4/BA.5-Adapted BNT162b2 Booster in ≥12-Year-Olds
2023 · Lisa Usdan, Sohil Patel, et al. · Clinical Infectious Diseases · 19
PDF
A randomized, controlled non-inferiority trial comparing A(H1N1)pmd09 vaccine antigen, with and without AS03 adjuvant system, co-administered or sequentially administered with an inactivated trivalent seasonal influenza vaccine
2012 · Joanne M Langley, Louise Frenette, et al. · BMC Infectious Diseases · 17
PDF
Immunogenicity of heterologous H5N1 influenza booster vaccination 6 or 18 months after primary vaccination in adults: A randomized controlled clinical trial
2014 · Joanne M. Langley, Louise Frenette, et al. · Vaccine · 16
PDF
Evaluation of a primary course of H9N2 vaccine with or without AS03 adjuvant in adults: A phase I/II randomized trial
2017 · Anuradha Madan, Harry Collins, et al. · Vaccine · 15
PDF
Immunogenicity and safety of an AS03-adjuvanted H7N1 vaccine in healthy adults: A phase I/II, observer-blind, randomized, controlled trial
2017 · Anuradha Madan, Murdo Ferguson, et al. · Vaccine · 14
PDF
Efficacy and Safety of Ciprofloxacin Plus Fluocinolone Acetonide Among Patients With Acute Otitis Externa
2022 · Laurence Chu, Ana M. Acosta, et al. · JAMA Network Open · 13
Stable emulsion (SE) alone is an effective adjuvant for a recombinant, baculovirus-expressed H5 influenza vaccine in healthy adults: A Phase 2 trial
2017 · John J. Treanor, Laurence Chu, et al. · Vaccine · 12
Safety and immunogenicity of a serum-free purified Vero rabies vaccine in healthy adults: A randomised phase II pre-exposure prophylaxis study
2022 · Sylvie Pichon, Annick Moureau, et al. · Vaccine · 11
PDF
Usability of daily SF36 questionnaires to capture the QALD variation experienced after vaccination with AS03A-adjuvanted monovalent influenza A (H5N1) vaccine in a safety and tolerability study
2019 · B. Standaert, T. Dort, et al. · Health and Quality of Life Outcomes · 9
PDF
Evaluating the Test-Negative Design for COVID-19 Vaccine Effectiveness Using Randomized Trial Data
2025 · Leah I. B. Andrews, M. Elizabeth Halloran, et al. · JAMA Network Open · 8
PDF
Works count: 31
Citation count: 1,643
H-index: 17
I10-index: 23
Year
Topic
Type